Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150500 | 0.93 | RXFP1 (0.54) | LMNARXFP1MPOMAPTKCNK3 | |
| SCHEMBL7152098 | 0.89 | RXFP1 (0.65) | LMNARXFP1MPOMAPTKCNK3 | |
| SCHEMBL7150586 | 0.86 | MAPT (0.60) | LMNARXFP1MPOMAPTKCNK3 | |
| SCHEMBL7147453 | 0.82 | RXFP1 (0.61) | LMNARXFP1MPOMAPTLCK | |
| SCHEMBL7154486 | 0.81 | LMNA (0.63) | LMNARXFP1MPOMAPTKCNK3 | |
| SCHEMBL6813680 | 0.81 | RXFP1 (0.53) | LMNARXFP1MAPTKCNK3POLB | |
| SCHEMBL7155509 | 0.80 | LMNA (0.62) | LMNARXFP1MPOMAPTKCNK3 | |
| SCHEMBL7150180 | 0.79 | RXFP1 (0.60) | RXFP1MPOMAPTLCKKIT | |
| SCHEMBL7154124 | 0.78 | RXFP1 (0.59) | LMNARXFP1MPOMAPTLCK | |
| SCHEMBL4517587 | 0.78 | LMNA (1.00) | LMNARXFP1MAPTKCNK3P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | claimed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | claimed |
| US-6528528-B2 | Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | disclosed |
| US-6268387-B1 | INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. | WARNER-LAMBERT COMPANY | 2001-07-31 | — | — | US | disclosed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | TPMT, CTH, CBS | LMNA 1617/4885RXFP1 2130/4885MPO 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.